LabGenius Therapeutics, a pioneer in machine learning (ML)-driven antibody engineering, has entered into a multi-year research collaboration, option, and license agreement with global chemical and life sciences leader LG Chem. The alliance centers on designing next-generation, multi-specific antibodies that bypass the fundamental challenges of current cancer treatments, specifically minimizing on-target, off-tumor toxicities. The joint operation will focus on developing a highly selective, tumor-targeted therapeutic aimed at a solid tumor antigen prevalent in several aggressive, hard-to-treat malignancies.
“The partnership with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to develop highly optimized, multi-specific antibodies,” explained Dr. James Field, CEO of LabGenius. “We welcome this opportunity to leverage our proprietary detection capabilities to advance the development of safer and more effective immunotherapies for patients with solid tumors.”
The research initiative integrates LabGenius’s automated “design-build-test-learn” loop with LG Chem‘s extensive oncology validation infrastructure. By executing continuous optimization cycles-where machine learning models design antibodies that are instantly validated via high-throughput robotic wet labs-the partnership aims to cut the traditional five-plus-year antibody discovery timeline in half.
Also Read: onsemi Acquire Synaptics Incorporated to Advance Intelligent Systems for Physical AI
Jineon So, Head of R&D, Life Sciences Division at LG Chem, commented on the development, saying: “LabGenius has a highly powerful and systematic platform that enables rapid candidate exploration and early evaluation through a closed-loop structure equipped with automated wet labs and computerized dry labs. Through this collaboration, we aim to rapidly identify novel cancer drug candidates with improved efficacy and reduced toxicity in areas of high unmet medical need.”
The cross-border corporate alliance also draws backing from international scientific leadership, highlighting a broader macroeconomic push toward embedding computational systems within traditional healthcare models to alleviate substantial disease burdens.
Science Minister Lord Vallance explained: “Over the course of our lives, cancer will affect many of us or our families, but from drug development to faster diagnoses, emerging technologies such as AI are revolutionizing our human ability to treat and cure this terrible disease. By combining machine learning with scientific research expertise, this collaboration has the potential to deliver new treatments that are more efficient and have fewer side effects – potentially improving treatment outcomes for patients around the world.”
Under the sequential operational framework of the agreement, LabGenius will shepherd the early-stage pipeline through preclinical discovery, delivering comprehensive in vitro efficacy data. Upon completion of this phase, LG Chem will assume responsibility for downstream preclinical execution, managing all in vivo evaluation models, and will retain an exclusive option to officially in-license the resulting therapeutic assets.
Financially, LG Chem has committed to completely funding all joint research and development initiatives. LabGenius is set to receive an undisclosed upfront payment alongside early-stage discovery milestones. Should LG Chem exercise its commercial option, LabGenius stands to gain triple-digit million-dollar milestone payments tied to clinical development, global regulatory approvals, and commercialization milestones, in addition to tiered royalties on future net sales.